177 related articles for article (PubMed ID: 35115359)
1. BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.
Bönhof GJ; Sipola G; Strom A; Herder C; Strassburger K; Knebel B; Reule C; Wollmann JC; Icks A; Al-Hasani H; Roden M; Kuss O; Ziegler D
BMJ Open; 2022 Feb; 12(2):e057142. PubMed ID: 35115359
[TBL] [Abstract][Full Text] [Related]
2. Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: A double-blind, randomized, placebo-controlled, parallel group pilot study over 12 months.
Stirban OA; Zeller-Stefan H; Schumacher J; Gaus W; Ziegler D; Schuerholz T; Pop-Busui R
J Diabetes Complications; 2020 Dec; 34(12):107757. PubMed ID: 33069584
[No Abstract] [Full Text] [Related]
3. A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes.
Stirban A; Pop A; Tschoepe D
Diabet Med; 2013 Oct; 30(10):1204-8. PubMed ID: 23701274
[TBL] [Abstract][Full Text] [Related]
4. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).
Haupt E; Ledermann H; Köpcke W
Int J Clin Pharmacol Ther; 2005 Feb; 43(2):71-7. PubMed ID: 15726875
[TBL] [Abstract][Full Text] [Related]
5. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.
Stracke H; Gaus W; Achenbach U; Federlin K; Bretzel RG
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):600-5. PubMed ID: 18473286
[TBL] [Abstract][Full Text] [Related]
6. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).
Feldman HH; Luchsinger JA; Léger GC; Taylor C; Jacobs DM; Salmon DP; Edland SD; Messer K; Revta C; Flowers SA; Jones KS; Koulman A; Yarasheski KE; Verghese PB; Venkatesh V; Zetterberg H; Durant J; Lupo JL; Gibson GE;
PLoS One; 2024; 19(5):e0302998. PubMed ID: 38809849
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of high-dose intramuscular vitamin D
Chen T; Xing X; Huang L; Tu M; Lai X; Wen S; Cai J; Lin S; Zheng Y; Lin Y; Xu L; Qiu Y; Qiu L; Xu Y; Wu P
Front Endocrinol (Lausanne); 2023; 14():1202917. PubMed ID: 37484958
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
Polydefkis M; Arezzo J; Nash M; Bril V; Shaibani A; Gordon RJ; Bradshaw KL; Junor RW;
J Peripher Nerv Syst; 2015 Dec; 20(4):363-71. PubMed ID: 26313450
[TBL] [Abstract][Full Text] [Related]
9. Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: A randomized double-blind placebo- controlled clinical trial.
Asadi S; Gholami MS; Siassi F; Qorbani M; Khamoshian K; Sotoudeh G
Complement Ther Med; 2019 Apr; 43():253-260. PubMed ID: 30935539
[TBL] [Abstract][Full Text] [Related]
10. Corneal confocal microscopy as a non-invasive test to assess diabetic peripheral neuropathy.
Xiong Q; Lu B; Ye HY; Liu SY; Zheng HP; Zhang RY; Qiao XN; Zhang S; Liu XX; Li QC; Yi N; Wu LC; Wen J; Zhang TS; Li YM
Diabetes Res Clin Pract; 2018 Feb; 136():85-92. PubMed ID: 29221815
[TBL] [Abstract][Full Text] [Related]
11. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial.
Fraser DA; Diep LM; Hovden IA; Nilsen KB; Sveen KA; Seljeflot I; Hanssen KF
Diabetes Care; 2012 May; 35(5):1095-7. PubMed ID: 22446172
[TBL] [Abstract][Full Text] [Related]
12. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy.
Maalmi H; Strom A; Petrera A; Hauck SM; Strassburger K; Kuss O; Zaharia OP; Bönhof GJ; Rathmann W; Trenkamp S; Burkart V; Szendroedi J; Ziegler D; Roden M; Herder C;
Diabetologia; 2023 Mar; 66(3):579-589. PubMed ID: 36472640
[TBL] [Abstract][Full Text] [Related]
13. Thiamine as adjunctive therapy for diabetic ketoacidosis (DKAT) trial protocol and statistical analysis plan: a prospective, single-centre, double-blind, randomised, placebo-controlled clinical trial in the USA.
Vine J; Mehta S; Balaji L; Berg KM; Berlin N; Liu X; Ngo L; Shea M; Moskowitz A; Donnino MW; Grossestreuer AV
BMJ Open; 2024 Feb; 14(2):e077586. PubMed ID: 38423765
[TBL] [Abstract][Full Text] [Related]
14. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations.
Ziegler D; Tesfaye S; Spallone V; Gurieva I; Al Kaabi J; Mankovsky B; Martinka E; Radulian G; Nguyen KT; Stirban AO; Tankova T; Varkonyi T; Freeman R; Kempler P; Boulton AJ
Diabetes Res Clin Pract; 2022 Apr; 186():109063. PubMed ID: 34547367
[TBL] [Abstract][Full Text] [Related]
15. Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial.
Bosi E; Bax G; Scionti L; Spallone V; Tesfaye S; Valensi P; Ziegler D;
Diabetologia; 2013 Mar; 56(3):467-75. PubMed ID: 23238789
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of corneal sub-epithelial microneuromas and axonal swelling in people with diabetes with and without (painful) diabetic neuropathy.
Sierra-Silvestre E; Andrade RJ; Colorado LH; Edwards K; Coppieters MW
Diabetologia; 2023 Sep; 66(9):1719-1734. PubMed ID: 37301795
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
18. Perineural injections of incobotulinumtoxin-A for diabetic neuropathic pain of the lower extremities: protocol for a phase II, single-centre, double-blind, randomised, placebo-controlled trial (the PINBOT study).
Klee M; Hørmann Thomsen T; Enggaard TP; Bitsch MS; Simonsen L; Jensen RH; Biering-Sørensen B
BMJ Open; 2024 Jan; 14(1):e074372. PubMed ID: 38262642
[TBL] [Abstract][Full Text] [Related]
19. A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.
Casselini CM; Parson HK; Frizzi KE; Marquez A; Smith DR; Guernsey L; Nemmani R; Tayarani A; Jolivalt CG; Weaver J; Fernyhough P; Vinik AI; Calcutt NA
Acta Neuropathol; 2024 Mar; 147(1):60. PubMed ID: 38526612
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
